Absence of both CD56 and CD117 expression on malignant plasma cells is related with a poor prognosis in patients with newly diagnosed multiple myeloma

Pan, Ying; Wang, Huiping; Tao, Qianshan; Zhang, Cui; Yang, Dongdong; Qin, Hui; Xiong, Sheng; Tao, Lili; Wu, Fan; Zhang, Jiakui; Zhai, Zhimin

doi:10.1016/j.leukres.2015.11.003

Cited by 38 publications

(59 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Variable or even discrepant results have been reported in the past regarding the precise immunophenotype of myeloma cells [3,4,6,7,9,10,16]. Heterogeneous results can be explained, at least to some extent, on methodological grounds, because of the different staining profiles obtained with the use of distinct monoclonal antibody (MoAb) reagents, the relatively high and variable baseline auto-fluorescence levels of clonal plasma cells, inappropriate study designs, lack of assay standardization, and lack of intra-assay quality checks of the whole cell sample via simultaneous detection of B-cell precursors, erythroblasts, myeloid precursors, and/or mast cells [17].…”

Section: Discussionmentioning

confidence: 99%

“…The results regarding the prognostic importance of CD56 expression are conflicting. Studies using induction treatment without novel agents have shown that the lack of CD56 expression in MM leads to more aggressive disease, with a tendency to develop plasma cell leukemia and is associated with a shorter progression-free survival (PFS) and overall survival (OS) [5,7,8]. In contrast to these reports, later studies including the largest prospective study by PETHEMA/GEM including 685 patients suggest that aHSCT overcomes the adverse influence of the lack of CD56 [4,9,10].…”

Section: Introductionmentioning

confidence: 99%

“…CD117 is a tyrosine kinase receptor, a cellular marker expressed in 30% of MM cases [7,10]. The lack of CD117 expression is associated with higher levels of bone marrow infiltration, renal impairment, elevated β2-microglobulin, and cytogenetic aberrations including t (11; 14), t(4; 14), and del(13q) [10].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction

et al. 2018

View full text Add to dashboard Cite

Objectives: In this retrospective study, we evaluated the impact of CD56, CD117, and CD28 expression on clinical characteristics and survival in newly diagnosed myeloma patients treated with bortezomib-based induction therapy. Methods: We analyzed 110 myeloma patients. Immunophenotype was determined using panels consisting of CD19/CD38/CD45/CD56/CD138 and CD20, CD28, and CD117 were used additionally. All samples were tested for recurrent chromosomal aberrations. Results: CD56, CD117, and CD28 expression rates were 71, 6, and 68%, respectively. The lack of CD56 expression was associated with light chain myeloma. The lack of CD117 expression was associated with elevated creatinine levels (p = 0.037). We discovered the correlation between CD 28 expression and female gender. The median progression-free survival (PFS) for patients with revised International Staging System stage 2 disease with CD56 expression or the lack of CD56 expression was 20.5 vs. 13.8 months (p = 0.03). In patients undergoing autologous hematopoietic stem cell transplantation (aHSCT), we found no difference in PFS and overall survival regarding the CD56 expression. We found no impact of CD117 and CD28 expression on PFS in patients regarding aHSCT. Conclusions: Induction treatment incorporating bortezomib diminishes the negative impact of the lack of CD117 expression and aberrancy of CD28 but does not overcome the negative impact of the lack of CD56 expression.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Mesenchymal stromal cells provide niches for hematopoietic stem cells by, inter alia , the expression of adhesion molecules comprising CD56, maintaining long-term hematopoiesis (7, 8). On the other hand, aberrant CD56 expression is seen in a range of hematological malignancies [e.g., multiple myeloma and leukemia (9, 10)] as well as solid tumors [e.g., lung cancer, ovarian cancer, and neuroblastoma (11–13)]. Moreover, numerical and functional deficiencies and phenotypic alterations of CD56 + immune cells have been reported in patients with various infectious, autoimmune or malignant diseases (Table 1).…”

Section: Introductionmentioning

confidence: 99%

CD56 in the Immune System: More Than a Marker for Cytotoxicity?

et al. 2017

View full text Add to dashboard Cite

Over the past years, the phenotypic and functional boundaries distinguishing the main cell subsets of the immune system have become increasingly blurred. In this respect, CD56 (also known as neural cell adhesion molecule) is a very good example. CD56 is the archetypal phenotypic marker of natural killer cells but can actually be expressed by many more immune cells, including alpha beta T cells, gamma delta T cells, dendritic cells, and monocytes. Common to all these CD56-expressing cell types are strong immunostimulatory effector functions, including T helper 1 cytokine production and an efficient cytotoxic capacity. Interestingly, both numerical and functional deficiencies and phenotypic alterations of the CD56+ immune cell fraction have been reported in patients with various infectious, autoimmune, or malignant diseases. In this review, we will discuss our current knowledge on the expression and function of CD56 in the hematopoietic system, both in health and disease.

show abstract

“…In recent years, some studies assessed the relationship between MM prognosis and the expression of CD56 9-11 . Pan et al retrospectively assessed the importance of CD56 as a prognostic factor in 50 newly diagnosed MM patients 11 . They found that patients with CD56 expression had a better overall response rate (p = 0.024).…”

Section: Introductionmentioning

confidence: 99%

Prognostic Value of CD56 Expression in Multiple Myeloma

Khallaf

Yousof

Ahmed

et al. 2020

Kasr-Al-Aini J.of Clin. Onc. and Nuc. Med.

View full text Add to dashboard Cite

Background: Understanding the prognostic markers of multiple myeloma (MM) helps in optimizing therapeutic approaches. CD56 is frequently expressed by malignant plasma cells and its use as a prognostic marker in MM is promising. Aim: To evaluate prognostic value of CD56 expression in patients with MM. Methods: This study included 50 newly diagnosed patients with MM. Bone marrow samples were analyzed for CD56 expression by flow cytometry. All patients received bortezomib-based therapy for at least 3-4 months. Results: The median age of patients was 52 years (range 32-75) and 54% of them were males. The stage according to the International Staging System was I in 15 (30%) patients, II in 18 (36%) and III in 17 (34%). CD56 positivity was detected in 84% of enrolled patients. Multivariate analysis revealed that the lack of CD56 expression was an independent predictor of worse overall survival (HR = 4.31 [95% Confidence Interval: 1.23 -15.13], p = 0.002). Conclusion:The present study suggests that CD56 negativity is associated with poor prognosis in patients with MM and that its incorporation in the risk panel of MM may be considered. Further studies with larger sample size to validate its prognostic value are needed.

show abstract

Absence of both CD56 and CD117 expression on malignant plasma cells is related with a poor prognosis in patients with newly diagnosed multiple myeloma

Cited by 38 publications

References 14 publications

CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction

CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction

CD56 in the Immune System: More Than a Marker for Cytotoxicity?

Prognostic Value of CD56 Expression in Multiple Myeloma

Contact Info

Product

Resources

About